¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå : À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åë ä³Îº°, Áö¿ªº°
Global Epinephrine Autoinjector Market, By Type, By End User, By Distribution Channel, By Geography
»óǰÄÚµå
:
1708601
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ¼¼°è ½ÃÀåÀº 2025³â¿¡ 27¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 49¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2032³â µ¿¾È 8.8%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í¼ ¹üÀ§ |
º¸°í¼ »ó¼¼ |
±âÁØ ¿¬µµ |
2024³â |
2025³â ½ÃÀå ±Ô¸ð |
27¾ï 4,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR |
8.80% |
2032³â ±Ý¾× ¿¹Ãø |
49¾ï 5,000¸¸ ´Þ·¯ |
±×¸². ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ¼¼°è ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2025³â

¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â´Â ¾Æ³ªÇʶô½Ã½º¸¦ Æ÷ÇÔÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀÇ ÀÀ±ÞÄ¡·á¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ÀÏȸ¿ë ÀÚµ¿ÁÖ»ç±âÀÔ´Ï´Ù. ¾Æ³ªÇʶô½Ã½º´Â ƯÁ¤ À½½Ä, ÀǾàǰ, ¹ú·¹ ¹°¸², ±âŸ ¾Ë·¹¸£°Õ¿¡ ´ëÇÑ ±Ø½ÉÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â »ý¸íÀ» À§ÇùÇÏ´Â »óÅÂÀÔ´Ï´Ù. ¾Æ³ªÇʶô½Ã½ºÀÇ Áõ»óÀ¸·Î´Â Ç÷¾Ð ÀúÇÏ, ÀÔ°ú ¸ñÀÇ ºÎÁ¾, ¹ßÁø, È£Èí°ï¶õ, ¼îÅ© µîÀÌ ÀÖ½À´Ï´Ù. ¾Æ³ªÇʶô½Ã½ºÀÇ °æ¿ì, Áõ»óÀÇ ÁøÇàÀ» ¾ïÁ¦Çϱâ À§ÇØ ¿¡Çdz×ÇÁ¸°À» Àû½Ã¿¡ Åõ¿©ÇØ¾ß ÇÕ´Ï´Ù. ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â´Â ÁÖ»ç±â¿¡ ºñÇØ ¿¡Çdz×ÇÁ¸°À» ½Å¼ÓÇÏ°Ô ÀÚµ¿ Åõ¿©ÇÒ ¼ö ÀÖ¾î Àθí ÇÇÇØÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ
FAAN(The Food Allergy and Anaphylaxis Network)ÀÌ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, ¹Ì±¹¿¡¼¸¸ ¿¬°£ 5¸¸ °ÇÀÇ ¾Æ³ªÇʶô½Ã½º°¡ ¹ß»ýÇϸç, ±× Áß 150-200¸íÀÌ »ç¸ÁÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ±× Áß 150-200°ÇÀÌ »ç¸Á¿¡ À̸£°í ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±â¿Í °ü·ÃµÈ »ý¸íÀ» À§ÇùÇÏ´Â Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÷´Ü ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±âÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ÀåÄ¡ÀÇ ºñ¿ë°ú ½ÅÈï±¹ÀÇ ´ëü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. Çâ»óµÈ »ç¿ë ÆíÀǼº, Á¤È®¼º, ´õ ³ÐÀº Àû¿ë ¹üÀ§¸¦ °®Ãá Çõ½ÅÀûÀÎ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±âÀÇ °³¹ßÀº ÇâÈÄ ¸î ³â µ¿¾È Á¦Á¶¾÷ü¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀº ±â¼ú ¹ßÀü, ¾Æ³ªÇʶô½Ã½º¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, »ç¿ëÀÚ Ä£ÈÀûÀÎ µðÀÚÀο¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ ÁÖ¸ñÇÒ ¸¸ÇÑ Ãß¼¼¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. ¹Ù´Ã ¾ø´Â ´ëüǰ ¹× ÈÆ·Ã¿ë µðÁöÅÐ Çコ Ç÷§ÆûÀÌ °¢±¤À» ¹Þ°í ÀÖÀ¸¸ç, ȯÀÚÀÇ ÆíÀǼº°ú Á¢±Ù¼ºÀ» Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ½Ã½ºÅÛ ¹× °ø±Þ¸Á¿¡ ´ëÇÑ ÀûÀÀ·ÂÀ» ÇÊ¿ä·Î ÇÏ´Â ÆÒµ¥¹ÍÀÇ ¿µÇâÀ» ¹Þ¾Æ ÁøÈÇÏ´Â »óȲ¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å, ±â±â ±â´É °³¼±, Àü·«Àû Á¦ÈÞ°¡ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀÇ ¿ªÇÐÀ» Çü¼ºÇϰí ÀÖÀ¸¸ç, ±Þº¯ÇÏ´Â ÀÇ·á ȯ°æ¿¡¼ À§Çè¿¡ óÇÑ °³Àΰú ÀÇ·á ¼ºñ½º Á¦°øÀÚÀÇ ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
¼¼°è ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀÇ ÁÖ¿ä ¾÷ü¸¦ ȸ»ç °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
ÁÖ¿ä ±â¾÷À¸·Î´Â Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, Kaleo µîÀÌ ÀÖ½À´Ï´Ù. Kaleo µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
¼¼°è ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÌÇØ°ü°èÀÚµéÀº ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- Coherent Opportunity Map(COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¿µÇ⠺м®
- ±ÔÁ¦ ½Ã³ª¸®¿À
- ¼ºñ½º Á¦°ø Æ÷Æ®Æú¸®¿À
- PEST ºÐ¼®
- Porters ºÐ¼®
- ÀμöÇÕº´ ½Ã³ª¸®¿À
- ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- COVID-19 ¿ªÇÐ
- °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
- °æÁ¦¿¡ ´ëÇÑ ¿µÇâ
Á¦5Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå, À¯Çüº°, 2020-2032³â
Á¦6Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â
- ¼Ò°³
- º´¿ø
- Ŭ¸®´Ð
- °³ÀÎ °í°´
Á¦7Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â
- ¼Ò°³
- ¼Ò¸Å ¾à±¹
- º´¿ø ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
Á¦8Àå ¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚµ¿ÁÖ»ç±â ½ÃÀå, Áö¿ªº°, 2020-2032³â
- ¼Ò°³
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- 秵- ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï ±¸µµ
- Mylan
- Teva Pharmaceutical
- Impax Laboratories
- Adamis Pharmaceuticals Corporation
- Pfizer
- ALK Abello
- Lincoln Medical
- Hospira
- Sanofi
- Kaleo
Á¦10Àå ¼½¼Ç
ksm
¿µ¹® ¸ñÂ÷
Global Epinephrine Autoinjector Market is estimated to be valued at USD 2.74 Bn in 2025 and is expected to reach USD 4.95 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 2.74 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
8.80% |
2032 Value Projection: |
USD 4.95 Bn |
Figure. Global Epinephrine Autoinjector Market Share (%), By Region 2025

Epinephrine autoinjector is a single-use disposable automatic injection device that is intended for emergency treatment of allergic reactions including anaphylaxis. Anaphylaxis is a life-threatening condition that occur due to an extreme allergic reaction to certain foods, medicines, insects bites and other allergens. The symptoms of anaphylaxis include low blood pressure, swelling of the mouth or throat, rashes, breathing difficulty and shock. In case of anaphylaxis, epinephrine needs to be administered in a timely manner to curb the advancement of symptoms. Epinephrine autoinjectors enable rapid self-administration of epinephrine as compared to syringes, thereby, reducing the risk of casualty.
Market Dynamics:
Global epinephrine autoinjector market growth is driven by rising prevalence of anaphylaxis worldwide. According to the data published by FAAN (The Food Allergy and Anaphylaxis Network), 50,000 cases of anaphylaxis occur annually in the U.S. alone, out of which 150-200 result in death. Increased awareness regarding life-threatening conditions associated with allergies along with availability of advanced epinephrine autoinjector devices are fueling the market demand. However, cost of these devices and preference for alternative treatment options in developing nations limits the market growth. Development of innovative epinephrine autoinjectors with improved usability, accuracy and larger coverage area is expected to present lucrative opportunities for manufacturers in the coming years.
The epinephrine autoinjector market is witnessing notable trends, driven by advancements in technology, increased awareness of anaphylaxis, and a growing emphasis on user-friendly designs. Needle-free alternatives and digital health platforms for training are gaining prominence, enhancing patient comfort and accessibility. The market is also responding to the evolving landscape influenced by the pandemic, necessitating adaptability in healthcare systems and supply chains. Continuous innovation, improved device features, and strategic collaborations are further shaping the dynamics of the epinephrine autoinjector market, aiming to address the needs of at-risk individuals and healthcare providers in a rapidly changing healthcare environment.
Key features of the study:
This report provides in-depth analysis of the global epinephrine autoinjector market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global epinephrine autoinjector market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, and Kaleo
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global epinephrine autoinjector market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epinephrine autoinjector market
Detailed Segmentation:
- Global Epinephrine Autoinjector Market, By Type
- Global Epinephrine Autoinjector Market, By End-User
- Hospitals
- Clinics
- Individual Customers
- Global Epinephrine Autoinjector Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- Global Epinephrine Autoinjector Market, By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles
- Mylan
- Teva Pharmaceutical
- Impax Laboratories
- Adamis Pharmaceuticals Corporation
- Pfizer
- ALK Abello
- Lincoln Medical
- Hospira
- Sanofi
- kaleo
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Epinephrine Autoinjector Market, By Type
- Global Epinephrine Autoinjector Market, By End User
- Global Epinephrine Autoinjector Market, By Distribution Channel
- Global Epinephrine Autoinjector Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing prevalence of anaphylaxis
- Rising Prevalence of Food Allergies
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Service offering Portfolio
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Pipeline Analysis
4. Global Epinephrine Autoinjector Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Epinephrine Autoinjector Market, By Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- 0.15mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- 0.3mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- 0.5mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Epinephrine Autoinjector Market, By End User, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Individual Customers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global Epinephrine Autoinjector Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global Epinephrine Autoinjector Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Mylan
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Teva Pharmaceutical
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Impax Laboratories
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Adamis Pharmaceuticals Corporation
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- ALK Abello
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Lincoln Medical
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hospira
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Kaleo
- Company Highlights
- Type Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
°ü·ÃÀÚ·á